Jaap Goudsmit

InstitutionDepartment of Epidemiology
AddressBoston
Massachusetts
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 5 Covid-19 publications, with a maximum of 2 publications in February 2021
    All Publications
    Bar chart showing 319 publications over 27 distinct years, with a maximum of 28 publications in 1998
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Goudsmit J, van den Biggelaar AHJ, Koudstaal W, Hofman A, Koff WC, Schenkelberg T, Alter G, Mina MJ, Wu JW. Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program. Eur J Epidemiol. 2021 Jul; 36(7):753-762. PMID: 34117979.
      Citations:    Fields:    Translation:Humans
    2. Terzikhan N, Hofman A, Goudsmit J, Ikram MA. External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European population. Eur J Epidemiol. 2021 Mar; 36(3):319-324. PMID: 33634346.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Koff WC, Schenkelberg T, Williams T, Baric RS, McDermott A, Cameron CM, Cameron MJ, Friemann MB, Neumann G, Kawaoka Y, Kelvin AA, Ross TM, Schultz-Cherry S, Mastro TD, Priddy FH, Moore KA, Ostrowsky JT, Osterholm MT, Goudsmit J. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci Transl Med. 2021 02 03; 13(579). PMID: 33536277.
      Citations: 9     Fields:    Translation:HumansAnimals
    4. Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, Storm N, Bernett M, Tong P, Zuo T, Lin J, Zuiani A, Linde C, Suscovich T, Wesemann DR, Griffiths A, Desjarlais JR, Juelg BD, Goudsmit J, Bukreyev A, Baric R, Alter G. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight. 2021 01 11; 6(1). PMID: 33427208.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    5. Goudsmit J. The paramount importance of serological surveys of SARS-CoV-2 infection and immunity. Eur J Epidemiol. 2020 04; 35(4):331-333. PMID: 32318914.
      Citations: 9     Fields:    Translation:HumansCellsPHPublic Health
    6. Havenga MJ, Holterman L, Melis I, Smits S, Kaspers J, Heemskerk E, van der Vlugt R, Koldijk M, Schouten GJ, Hateboer G, Brouwer K, Vogels R, Goudsmit J. Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity. Biotechnol Bioeng. 2008 Jun 01; 100(2):273-83. PMID: 18512821.
      Citations: 15     Fields:    Translation:HumansCells
    7. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruif J, Peiris JS, Goudsmit J. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006 Jul; 3(7):e237. PMID: 16796401.
      Citations: 264     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    8. Bogaards JA, Putter H, Jan Weverling G, Ter Meulen J, Goudsmit J. The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis. Travel Med Infect Dis. 2007 Mar; 5(2):70-8. PMID: 17298911.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    9. van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb; 79(3):1635-44. PMID: 15650189.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    10. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004 Jun 26; 363(9427):2139-41. PMID: 15220038.
      Citations: 121     Fields:    Translation:HumansAnimalsCells